Summary: Evaluated carvedilol versus metoprolol in patients with systolic heart failure (EF < 35%), New York Heart Association Functional class II-IV symptoms, prior hospitalization for cardiac cause and optimal treatment with diuretics and ACE inhibitors.

The primary endpoint of all-cause mortality was reduced using carvedilol compared to metoprolol (17% reduction). There was no difference in the composite of all-cause mortality plus hospitalization and there was no difference in reported side-effects.

Original Publication:

Lancet. 2003 Jul 5;362(9377):7-13.

Eponym: Carvedilol Or Metoprolol European Trial